Document is current
Any future updates will be listed below
-
Authors
Lang, Jessica D.
Nguyen, Tuong Vi V.
Levin, Maren K.
Blas, Page E.
Williams, Heather L.
Rodriguez, Esther San Roman
Briones, Natalia
Mueller, Claudius
Selleck, William
Moore, Sarah
Zismann, Victoria L.
Hendricks, William P.D.
Espina, Virginia
O’Shaughnessy, Joyce
-
Funding
Funding for this research was provided by:
Takeda Oncology
Baylor Scott and White Dallas Foundation
- License Information
-
More Information
Article History
Received: 26 April 2023
Accepted: 4 July 2023
First Online: 25 July 2023
Declarations
:
: VE is a consultant for TheraLink Technologies, Inc. and has patent and/or royalty/license fee distributions from TheraLink Technologies, Inc., Ceres Nanoscience, and Fluidigm. JO received honoraria for consulting and/or advisory boards for AbbVie Inc., Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Carrick Therapeutics, Celgene Corporation, Clovis Oncology, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Prime Oncology, Roche, Samsung Bioepis, Sanofi, Seagen, Syndax Pharmaceuticals, Taiho Oncology, Takeda, TheraLink and Synthon.
: This study was endorsed by the ethical review committee at Baylor Scott and White Research Institute.
: Not applicable.
